Skip to main content
Premium Trial:

Request an Annual Quote

LifeSensors Licenses Proteomics Tech from Spanish Center

NEW YORK (GenomeWeb News) – Proteomics technologies company LifeSensors has licensed technology from Spain's CICbioGUNE research center for use in purifying ubiquitylated proteins that are unstable and difficult to characterize.

LifeSensors said on Tuesday that it signed a worldwide, exclusive license for the Tandem-repeated Ubiquitin Binding Entities (TUBEs) technology, which was developed at CICbioGUNE's proteomics unit.

These TUBEs proteins may be used to capture ubiquitin pathway proteins, which "play key roles in numerous diseases from neurodegeneration to cancer," the company said. The technology can be used to purify ubiquitylated proteins from cells, tissues, and organs, according to LifeSensors.

"We have successfully used the TUBEs to identify novel proteins modified by ubiquitin and protect ubiquitylated proteins from degradation, all without the need for inhibitors or overexpression techniques," CICbioGUNE's Group Leader of Proteomics Manuel Rodriguez said in a statement.

Financial terms of the agreement were not released.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.